| |
| |
|
| Insider
Information: |
Champsi Farah |
| Relationship: |
Director |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
27,970,466 |
|
|
Indirect Shares
|
2,373,959 |
|
|
| Direct
Value |
$166,585,368 |
|
|
|
Indirect Value
|
$7,591,697 |
|
|
| Total
Shares |
30,344,425 |
|
|
| Total
Value |
$174,177,065 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
10% Owner |
2005-08-08 |
45,087 |
2005-08-08 |
24,499 |
Premium* |
|
|
Viracta Therapeutics Ord Shs |
VIRX |
Former 10% Owner |
2010-06-30 |
15,487,876 |
2010-06-30 |
381,683 |
Premium* |
|
|
Corcept Therapeutics Inc |
CORT |
10% Owner |
2009-10-16 |
5,484,063 |
2009-10-16 |
180,204 |
Premium* |
|
|
Chimerix Inc |
CMRX |
Director |
2013-04-16 |
0 |
2013-10-23 |
1,714,330 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
27,507 |
Premium* |
|
|
Scynexis Inc |
SCYX |
10% Owner |
2014-05-07 |
1,240,575 |
2014-05-07 |
45,736 |
Premium* |
|
|
Zs Pharma, Inc. |
ZSPH |
10% Owner |
2014-06-23 |
3,230,090 |
2014-06-23 |
0 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
10% Owner |
2014-07-29 |
2,482,775 |
2014-07-29 |
0 |
Premium* |
|
|
Kite Pharma, Inc. |
KITE |
Director |
2017-10-03 |
0 |
2017-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VIRX |
Viracta Therapeutics Ord ... |
10% Owner |
– – • |
2009-12-14 |
4 |
S |
$2.01 |
$4,108,721 |
D/D |
(2,044,750) |
0 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
10% Owner |
– – • |
2009-12-14 |
4 |
S |
$2.01 |
$377,193 |
I/I |
(187,714) |
0 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-16 |
4 |
S |
$88.11 |
$480,200 |
I/I |
(5,450) |
0 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-10-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,807) |
0 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-10-03 |
4 |
D |
$180.00 |
$11,064,060 |
D/D |
(61,467) |
1,807 |
0 |
- |
|
| SCYX |
Scynexis Inc |
10% Owner |
– – • |
2014-05-07 |
4 |
OE |
$0.20 |
$676 |
I/I |
3,381 |
3,381 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-28 |
4 |
S |
$82.59 |
$216,138 |
I/I |
(2,617) |
4,962 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-27 |
4 |
S |
$82.77 |
$1,369,926 |
I/I |
(16,551) |
7,579 |
0 |
- |
|
| SCYX |
Scynexis Inc |
10% Owner |
– – • |
2014-05-07 |
4 |
A |
$0.00 |
$0 |
I/I |
10,421 |
13,802 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,950 |
21,616 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-26 |
4 |
S |
$82.72 |
$4,244,597 |
I/I |
(51,312) |
24,130 |
0 |
- |
|
| RNVS |
Renovis Inc |
No longer 10% Owner |
– – – |
2005-08-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
24,499 |
|
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2013-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,218,683 |
27,507 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
2,166,112 |
42,240 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
38,257 |
42,702 |
|
- |
|
| RNVS |
Renovis Inc |
No longer a Director |
– – – |
2005-08-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,385 |
45,087 |
|
- |
|
| SCYX |
Scynexis Inc |
10% Owner |
– – • |
2014-05-07 |
4 |
B |
$10.00 |
$319,340 |
I/I |
31,934 |
45,736 |
1.5 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-09-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,800 |
63,274 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-14 |
4 |
S |
$90.40 |
$1,356,000 |
D/D |
(15,000) |
63,664 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
66,074 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-25 |
4 |
S |
$82.56 |
$3,873,585 |
I/I |
(46,783) |
75,442 |
0 |
- |
|
| SCYX |
Scynexis Inc |
10% Owner |
– – • |
2014-05-07 |
4 |
OE |
$0.20 |
$18,311 |
D/D |
91,556 |
91,556 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-24 |
4 |
S |
$82.34 |
$2,125,854 |
I/I |
(25,818) |
122,225 |
0 |
- |
|
| KITE |
Kite Pharma, Inc. |
Director |
– • – |
2017-04-17 |
4 |
S |
$82.48 |
$3,555,028 |
I/I |
(43,101) |
148,043 |
0 |
- |
|
43 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
